Mirum Pharmaceuticals Raises $600M in Convertible Notes, Refinances Debt
Event summary
- Mirum Pharmaceuticals priced a $600M offering of 0.00% convertible senior notes due 2032, with an option for an additional $90M.
- The notes carry an initial conversion price of $138.94 per share, a 30% premium over the last reported price of $106.88.
- Mirum will use $475M of the proceeds to refinance $237.2M of its 2029 convertible notes and the remainder for general corporate purposes.
- The transaction includes a note exchange where Mirum will issue 3.2M shares of common stock in exchange for the 2029 notes.
The big picture
Mirum Pharmaceuticals' $600M convertible notes offering and debt refinancing reflect a strategic move to optimize its capital structure amid a focus on growth. The transaction underscores the company's efforts to manage its financial obligations while positioning itself for potential acquisitions or expansions in the rare disease space. The scale of the offering highlights Mirum's access to institutional capital and its ability to navigate complex financial maneuvers in a competitive biotech landscape.
What we're watching
- Debt Management
- How Mirum's refinancing strategy will impact its balance sheet and financial flexibility.
- Market Impact
- Whether the unwinding of hedge positions by noteholders will affect Mirum's stock price volatility.
- Growth Strategy
- The pace at which Mirum will deploy the remaining proceeds for acquisitions or other strategic initiatives.
Related topics